Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in colombia
Plasmodium vivax malaria is an important cause of morbidity in Central and South America. In Colombia, this is the most prevalent malaria infection, representing 75% of the reported cases. To define the efficacy of the chloroquine and primaquine regimen to eliminate hypnozoites and prevent relapses,...
Gespeichert in:
| Veröffentlicht in: | The American journal of tropical medicine and hygiene 2006-10, Vol.75 (4), p.605-609 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 609 |
|---|---|
| container_issue | 4 |
| container_start_page | 605 |
| container_title | The American journal of tropical medicine and hygiene |
| container_volume | 75 |
| creator | ALVAREZ, Gonzalo PINEROS, Juan-Gabriel TOBON, Alberto RIOS, Alexandra MAESTRE, Amanda BLAIR, Silvia CARMONA-FONSECA, Jaime |
| description | Plasmodium vivax malaria is an important cause of morbidity in Central and South America. In Colombia, this is the most prevalent malaria infection, representing 75% of the reported cases. To define the efficacy of the chloroquine and primaquine regimen to eliminate hypnozoites and prevent relapses, we conducted a random controlled clinical trial of three primaquine regimens in an open-label study. We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P. vivax infection from the northwestern region of Colombia. Cure rates for blood-stage P. vivax malaria by day 28 of follow-up were 100% in all groups. Post-treatment reappearance of parasitemia during the six months of follow-up was 45%, 36.6% and 17.6%, respectively, for each group. When compared with other groups, administration of 210 mg was a significant protection factor for reappearance of parasitemia in a malaria-endemic area. |
| doi_str_mv | 10.4269/ajtmh.2006.75.605 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68956838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20548620</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-4259a2c159bf72407585843c22e109dcc46f382b649593e81e1311cce08cfbb73</originalsourceid><addsrcrecordid>eNqFkUtrGzEUhUVJqB23P6Cbok26G-fqOdKyBPcBhnaRrIVGlmKZ0ciVxib59x07hiyzuvfCdw7ccxD6QmDJqdR3djem7ZICyGUrlhLEBzQnvJUNkVxcoTkA0EZL1s7QTa07AKIoIR_RjLTAlFQwR0-rEKKz7gXngMdt8R67bZ9L_neIg2_2JSZ7XnHxTzH5oeKQCx6Lt-N0jSfZ397WlDfxkPAxHu0zTra3JVocB-xyn1MX7Sd0HWxf_efLXKDHH6uH-1_N-s_P3_ff143jwMaGU6EtdUToLrSUQyuUUJw5Sj0BvXGOy8AU7STXQjOviCeMEOc8KBe6rmUL9O3Vd396wdfRpFid73s7-HyoRiotpGLqXZCC4EpSmEDyCrqSay0-mHMo5cUQMKcazLkGc6rBtMJMNUyarxfzQ5f85k1xyX0Cbi-Arc72odjBxfrGKaKpFpT9B5Qikhc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20548620</pqid></control><display><type>article</type><title>Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in colombia</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>ALVAREZ, Gonzalo ; PINEROS, Juan-Gabriel ; TOBON, Alberto ; RIOS, Alexandra ; MAESTRE, Amanda ; BLAIR, Silvia ; CARMONA-FONSECA, Jaime</creator><creatorcontrib>ALVAREZ, Gonzalo ; PINEROS, Juan-Gabriel ; TOBON, Alberto ; RIOS, Alexandra ; MAESTRE, Amanda ; BLAIR, Silvia ; CARMONA-FONSECA, Jaime</creatorcontrib><description>Plasmodium vivax malaria is an important cause of morbidity in Central and South America. In Colombia, this is the most prevalent malaria infection, representing 75% of the reported cases. To define the efficacy of the chloroquine and primaquine regimen to eliminate hypnozoites and prevent relapses, we conducted a random controlled clinical trial of three primaquine regimens in an open-label study. We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P. vivax infection from the northwestern region of Colombia. Cure rates for blood-stage P. vivax malaria by day 28 of follow-up were 100% in all groups. Post-treatment reappearance of parasitemia during the six months of follow-up was 45%, 36.6% and 17.6%, respectively, for each group. When compared with other groups, administration of 210 mg was a significant protection factor for reappearance of parasitemia in a malaria-endemic area.</description><identifier>ISSN: 0002-9637</identifier><identifier>EISSN: 1476-1645</identifier><identifier>DOI: 10.4269/ajtmh.2006.75.605</identifier><identifier>PMID: 17038680</identifier><identifier>CODEN: AJTHAB</identifier><language>eng</language><publisher>Lawrence, KS: Allen Press</publisher><subject>Adult ; Animals ; Antimalarials - therapeutic use ; Biological and medical sciences ; Chloroquine - therapeutic use ; Colombia ; Female ; Follow-Up Studies ; Human protozoal diseases ; Humans ; Infectious diseases ; Malaria ; Malaria, Vivax - drug therapy ; Malaria, Vivax - prevention & control ; Male ; Medical sciences ; Parasitemia - drug therapy ; Parasitemia - prevention & control ; Parasitic diseases ; Plasmodium vivax ; Primaquine - therapeutic use ; Prospective Studies ; Protozoal diseases ; Secondary Prevention ; Treatment Outcome</subject><ispartof>The American journal of tropical medicine and hygiene, 2006-10, Vol.75 (4), p.605-609</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-4259a2c159bf72407585843c22e109dcc46f382b649593e81e1311cce08cfbb73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18192952$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17038680$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ALVAREZ, Gonzalo</creatorcontrib><creatorcontrib>PINEROS, Juan-Gabriel</creatorcontrib><creatorcontrib>TOBON, Alberto</creatorcontrib><creatorcontrib>RIOS, Alexandra</creatorcontrib><creatorcontrib>MAESTRE, Amanda</creatorcontrib><creatorcontrib>BLAIR, Silvia</creatorcontrib><creatorcontrib>CARMONA-FONSECA, Jaime</creatorcontrib><title>Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in colombia</title><title>The American journal of tropical medicine and hygiene</title><addtitle>Am J Trop Med Hyg</addtitle><description>Plasmodium vivax malaria is an important cause of morbidity in Central and South America. In Colombia, this is the most prevalent malaria infection, representing 75% of the reported cases. To define the efficacy of the chloroquine and primaquine regimen to eliminate hypnozoites and prevent relapses, we conducted a random controlled clinical trial of three primaquine regimens in an open-label study. We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P. vivax infection from the northwestern region of Colombia. Cure rates for blood-stage P. vivax malaria by day 28 of follow-up were 100% in all groups. Post-treatment reappearance of parasitemia during the six months of follow-up was 45%, 36.6% and 17.6%, respectively, for each group. When compared with other groups, administration of 210 mg was a significant protection factor for reappearance of parasitemia in a malaria-endemic area.</description><subject>Adult</subject><subject>Animals</subject><subject>Antimalarials - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chloroquine - therapeutic use</subject><subject>Colombia</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Malaria</subject><subject>Malaria, Vivax - drug therapy</subject><subject>Malaria, Vivax - prevention & control</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Parasitemia - drug therapy</subject><subject>Parasitemia - prevention & control</subject><subject>Parasitic diseases</subject><subject>Plasmodium vivax</subject><subject>Primaquine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Protozoal diseases</subject><subject>Secondary Prevention</subject><subject>Treatment Outcome</subject><issn>0002-9637</issn><issn>1476-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtrGzEUhUVJqB23P6Cbok26G-fqOdKyBPcBhnaRrIVGlmKZ0ciVxib59x07hiyzuvfCdw7ccxD6QmDJqdR3djem7ZICyGUrlhLEBzQnvJUNkVxcoTkA0EZL1s7QTa07AKIoIR_RjLTAlFQwR0-rEKKz7gXngMdt8R67bZ9L_neIg2_2JSZ7XnHxTzH5oeKQCx6Lt-N0jSfZ397WlDfxkPAxHu0zTra3JVocB-xyn1MX7Sd0HWxf_efLXKDHH6uH-1_N-s_P3_ff143jwMaGU6EtdUToLrSUQyuUUJw5Sj0BvXGOy8AU7STXQjOviCeMEOc8KBe6rmUL9O3Vd396wdfRpFid73s7-HyoRiotpGLqXZCC4EpSmEDyCrqSay0-mHMo5cUQMKcazLkGc6rBtMJMNUyarxfzQ5f85k1xyX0Cbi-Arc72odjBxfrGKaKpFpT9B5Qikhc</recordid><startdate>20061001</startdate><enddate>20061001</enddate><creator>ALVAREZ, Gonzalo</creator><creator>PINEROS, Juan-Gabriel</creator><creator>TOBON, Alberto</creator><creator>RIOS, Alexandra</creator><creator>MAESTRE, Amanda</creator><creator>BLAIR, Silvia</creator><creator>CARMONA-FONSECA, Jaime</creator><general>Allen Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>C1K</scope><scope>F1W</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>20061001</creationdate><title>Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in colombia</title><author>ALVAREZ, Gonzalo ; PINEROS, Juan-Gabriel ; TOBON, Alberto ; RIOS, Alexandra ; MAESTRE, Amanda ; BLAIR, Silvia ; CARMONA-FONSECA, Jaime</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-4259a2c159bf72407585843c22e109dcc46f382b649593e81e1311cce08cfbb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Antimalarials - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chloroquine - therapeutic use</topic><topic>Colombia</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Malaria</topic><topic>Malaria, Vivax - drug therapy</topic><topic>Malaria, Vivax - prevention & control</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Parasitemia - drug therapy</topic><topic>Parasitemia - prevention & control</topic><topic>Parasitic diseases</topic><topic>Plasmodium vivax</topic><topic>Primaquine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Protozoal diseases</topic><topic>Secondary Prevention</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ALVAREZ, Gonzalo</creatorcontrib><creatorcontrib>PINEROS, Juan-Gabriel</creatorcontrib><creatorcontrib>TOBON, Alberto</creatorcontrib><creatorcontrib>RIOS, Alexandra</creatorcontrib><creatorcontrib>MAESTRE, Amanda</creatorcontrib><creatorcontrib>BLAIR, Silvia</creatorcontrib><creatorcontrib>CARMONA-FONSECA, Jaime</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of tropical medicine and hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ALVAREZ, Gonzalo</au><au>PINEROS, Juan-Gabriel</au><au>TOBON, Alberto</au><au>RIOS, Alexandra</au><au>MAESTRE, Amanda</au><au>BLAIR, Silvia</au><au>CARMONA-FONSECA, Jaime</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in colombia</atitle><jtitle>The American journal of tropical medicine and hygiene</jtitle><addtitle>Am J Trop Med Hyg</addtitle><date>2006-10-01</date><risdate>2006</risdate><volume>75</volume><issue>4</issue><spage>605</spage><epage>609</epage><pages>605-609</pages><issn>0002-9637</issn><eissn>1476-1645</eissn><coden>AJTHAB</coden><abstract>Plasmodium vivax malaria is an important cause of morbidity in Central and South America. In Colombia, this is the most prevalent malaria infection, representing 75% of the reported cases. To define the efficacy of the chloroquine and primaquine regimen to eliminate hypnozoites and prevent relapses, we conducted a random controlled clinical trial of three primaquine regimens in an open-label study. We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P. vivax infection from the northwestern region of Colombia. Cure rates for blood-stage P. vivax malaria by day 28 of follow-up were 100% in all groups. Post-treatment reappearance of parasitemia during the six months of follow-up was 45%, 36.6% and 17.6%, respectively, for each group. When compared with other groups, administration of 210 mg was a significant protection factor for reappearance of parasitemia in a malaria-endemic area.</abstract><cop>Lawrence, KS</cop><pub>Allen Press</pub><pmid>17038680</pmid><doi>10.4269/ajtmh.2006.75.605</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9637 |
| ispartof | The American journal of tropical medicine and hygiene, 2006-10, Vol.75 (4), p.605-609 |
| issn | 0002-9637 1476-1645 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68956838 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Animals Antimalarials - therapeutic use Biological and medical sciences Chloroquine - therapeutic use Colombia Female Follow-Up Studies Human protozoal diseases Humans Infectious diseases Malaria Malaria, Vivax - drug therapy Malaria, Vivax - prevention & control Male Medical sciences Parasitemia - drug therapy Parasitemia - prevention & control Parasitic diseases Plasmodium vivax Primaquine - therapeutic use Prospective Studies Protozoal diseases Secondary Prevention Treatment Outcome |
| title | Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in colombia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A47%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20three%20chloroquine-primaquine%20regimens%20for%20treatment%20of%20Plasmodium%20vivax%20malaria%20in%20colombia&rft.jtitle=The%20American%20journal%20of%20tropical%20medicine%20and%20hygiene&rft.au=ALVAREZ,%20Gonzalo&rft.date=2006-10-01&rft.volume=75&rft.issue=4&rft.spage=605&rft.epage=609&rft.pages=605-609&rft.issn=0002-9637&rft.eissn=1476-1645&rft.coden=AJTHAB&rft_id=info:doi/10.4269/ajtmh.2006.75.605&rft_dat=%3Cproquest_cross%3E20548620%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20548620&rft_id=info:pmid/17038680&rfr_iscdi=true |